◼ Archived
Business
🔮 holds ✗
Lilly
12 independently sourced, verified news trends involving Lilly.
Coverage evidence
This hub is built from stories supported by at least four independent sources and accepted by Newsylist's verification pass. Qualifying coverage spans 1 news category, from Jul 21, 2026 through Oct 16, 2026.
Open any card for the source list, timeline and coverage-velocity evidence. Raw detections and extractive-only records are excluded from this page.
◼ Archived
Business
🔮 holds ✗
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
◼ Archived
Business
🔮 holds ✗
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
◼ Archived
Business
🔮 holds ✗
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
◼ Archived
Business
🔮 holds ✗
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
◼ Archived
Business
🔮 holds ✗
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
◼ Archived
Business
🔮 fades ✓
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
◼ Archived
Business
🔮 holds ✗
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
◼ Archived
Business
🔮 holds ✗
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
◼ Archived
Business
🔮 fades ✓
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
◼ Archived
Business
🔮 holds ✓
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
◼ Archived
Business
🔮 holds ✓
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.